Market Analysis
125 articles in this category (Page 6 of 6)
HealthcareClinical TrialsMarket Analysis
Novo Nordisk Faces Severe Headwinds Following CagriSema Trial Failure: 5-Day Bearish Outlook
Novo Nordisk's stock faces continued downward pressure after its weight-loss drug CagriSema missed trial goals against Eli Lilly, prompting a severe 2026 guidance cut.
NVO
Read more